Observational Registry of Patients With Von WilLEbrand Disease Treated With Voncento
Latest Information Update: 01 Mar 2024
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Von Willebrand disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms OPALE
- Sponsors CSL Behring
- 26 Feb 2024 Status changed from active, no longer recruiting to completed.
- 01 Jul 2022 Results assessing the effectiveness and safety of Voncento R, a plasma-derived FVIII/VWF concentrate (ratio 1:2.4), administrated in LTP published in the European Journal of Haematology
- 10 Jan 2022 Status changed from recruiting to active, no longer recruiting.